News

ModiQuest to Offer Ligand’s OmniAb Service in Europe

Victoria, British Columbia, Canada, October 15th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that ModiQuest® Research, an ImmunoPrecise Company, is now an OmniAb approved CRO, which enables ImmunoPrecise to offer OmniAb services in both the US and Europe. This approval allows ImmunoPrecise to further expand its … Continue reading

ImmunoPrecise Signs Large Pharma Antibody Development Agreement

Victoria, British Columbia, Canada, October 9th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has signed an agreement and initiated an antibody development program with an undisclosed, top 15, global pharmaceutical company, to discover novel antibodies using ImmunoPrecise’s proprietary hybridoma technology. ImmunoPrecise’s … Continue reading

ImmunoPrecise Announces Phage Display-Based Antibody Discovery Platforms

Victoria, British Columbia, Canada, October 2nd, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced the addition of in-house and custom phage libraries to their growing service offeringsthrough their recent expansion in Europe.  Through construction and screening of scFv and VHH phage display libraries, ImmunoPrecise is able to generate monoclonal … Continue reading

IMMUNOPRECISE ANTIBODIES’ Q1 REVENUES INCREASE 386% OVER Q1 2017

October 1st, 2018 - Victoria, British Columbia.  IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX Venture: IPA, Pink Sheets: IPATF) today reports its financial results for Q1 ended July 31, 2018.  The financial statements and related management’s discussion and analysis (“MD&A”) can be viewed on SEDAR at www.sedar.com. Financial Highlights: Revenue.During the three months ended July 31, 2018, the Company increased revenues to … Continue reading

IMMUNOPRECISE CLOSES OVERSUBSCRIBED PRIVATE PLACEMENT RAISING $9.1M

Victoria, British Columbia, Canada, September 28, 2018 - IMMUNOPRECISE ANTIBODIES LTD.(“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private placement financing by issuing a total of 9,102,500 units (“Units”) of ImmunoPrecise at a price of $1.00 per Unit for gross proceeds of $9,102,500 (the “Financing”).  Due to strong investor … Continue reading

Immunoprecise and Harbour Antibodies announce technology co-offering agreement for next-generation fully-human antibody discovery

Co-offering Agreement combines ImmunoPrecise’s advanced hybridoma plus B cell screening and sorting services with Harbour Antibodies’ patented H2L2 transgenic mouse platform Victoria, British Columbia, Canada, August 30th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) ImmunoPrecise Antibodies and Harbour Antibodies, a wholly owned subsidiary of Harbour BioMed, announced today … Continue reading

ImmunoPrecise Antibodies’ Annual Revenues Increase 106% to 5.4 Million

August 29, 2018 – Victoria, British Columbia.  IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX Venture: IPA, Pink Sheets: IPATF) today reports its financial results for the year ended April 30, 2018.  The financial statements and related management’s discussion and analysis (“MD&A”) can be viewed on SEDAR at www.sedar.com. Financial Highlights: Revenue. ImmunoPrecise achieved record annual revenue of … Continue reading

ImmunoPrecise Increases Private Placement Financing to $7 Million

Victoria, British Columbia, Canada, August 28, 2018 – IMMUNOPRECISE ANTIBODIES LTD.(“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has increased its previously announced non-brokered private placement financing (see news release dated August 22, 2018) to 7,000,000 units (“Units”) of ImmunoPrecise at a price of $1.00 per Unit for gross proceeds of $7,000,000 (the … Continue reading

IMMUNOPRECISE ANNOUNCES $2 MILLION FINANCING

Victoria, British Columbia, Canada, August 22, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it proposes to complete a non-brokered private placement financing of 2,000,000 units (“Units”) of ImmunoPrecise at a price of $1.00 per Unit for gross proceeds of $2,000,000 (the “Financing”). Each Unit will consist of … Continue reading

IMMUNOPRECISE ANNOUNCES THE RESIGNATION OF DIRECTOR

Victoria, British Columbia, Canada, August 20, 2018 - IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that Mr. Guy Champagne, has resigned from his position as a director, effective immediately, and will be joining ImmunoPrecise’s Advisory Board.  The Board of Directors would like to thank Mr. Champagne for all of his efforts as … Continue reading